{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:03:12Z","timestamp":1770822192960,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2003,2,1]]},"DOI":"10.1038\/sj.bmt.1703818","type":"journal-article","created":{"date-parts":[[2003,3,5]],"date-time":"2003-03-05T17:12:34Z","timestamp":1046884354000},"page":"163-170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients"],"prefix":"10.1038","volume":"31","author":[{"given":"E","family":"Terpos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J F","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Samson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Giles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Crawley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Kanfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Olavarria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J M","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Rahemtulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,2,5]]},"reference":[{"key":"BF1703818_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","volume":"51","author":"RT Greenlee","year":"2001","unstructured":"Greenlee RT, Hill-Harmon MB, Murray T, Thun M . Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15\u201336.","journal-title":"CA Cancer J Clin"},{"key":"BF1703818_CR2","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1200\/JCO.1992.10.2.334","volume":"10","author":"M Boccadoro","year":"1992","unstructured":"Boccadoro M, Marmont F, Tribalto M et al. Multiple myeloma: VMCP\/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1992; 10: 334\u2013342.","journal-title":"J Clin Oncol"},{"key":"BF1703818_CR3","doi-asserted-by":"crossref","unstructured":"Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6663 patients from 27 randomised trials. J Clin Oncol 1998; 16: 3832\u20133842.","DOI":"10.1200\/JCO.1998.16.12.3832"},{"key":"BF1703818_CR4","doi-asserted-by":"crossref","unstructured":"UK Myeloma Forum. British Committee for Standards in Haematology. Diagnosis and management of multiple myeloma. Br J Haematol 2001; 115: 522\u2013540.","DOI":"10.1046\/j.1365-2141.2001.03206.x"},{"key":"BF1703818_CR5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/0002-9343(85)90310-9","volume":"79","author":"HJ Cohen","year":"1985","unstructured":"Cohen HJ, Bartolucci A . Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience. Am J Med 1985; 79: 316\u2013324.","journal-title":"Am J Med"},{"key":"BF1703818_CR6","first-page":"238","volume":"81","author":"M Clavio","year":"1996","unstructured":"Clavio M, Casciaro S, Gatti AM et al. Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients. Haematologica 1996; 81: 238\u2013244.","journal-title":"Haematologica"},{"key":"BF1703818_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/bjc.1998.77","volume":"77","author":"A Riccardi","year":"1998","unstructured":"Riccardi A, Mora O, Brugnatelli S et al. Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomised protocol. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 1998; 77: 485\u2013491.","journal-title":"Br J Cancer"},{"key":"BF1703818_CR8","first-page":"291","volume":"81","author":"A Pileri","year":"1996","unstructured":"Pileri A, Palumbo A, Boccadoro M . Current therapeutic options for multiple myeloma. Haematologica 1996; 81: 291\u2013294.","journal-title":"Haematologica"},{"key":"BF1703818_CR9","first-page":"5","volume":"10","author":"D Quaglino","year":"1998","unstructured":"Quaglino D, Di Leonardo G, Pasqualoni E et al. Therapeutic management of hematological malignancies in elderly patients. Biological and clinical considerations. Part IV: multiple myeloma and Waldenstrom's macroglobulinemia. Aging (Milano) 1998; 10: 5\u201312.","journal-title":"Aging (Milano)"},{"key":"BF1703818_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91\u201397.","journal-title":"N Engl J Med"},{"key":"BF1703818_CR11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","volume":"93","author":"B Barlogie","year":"1999","unstructured":"Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55\u201365.","journal-title":"Blood"},{"key":"BF1703818_CR12","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.V94.4.1248","volume":"94","author":"A Palumbo","year":"1999","unstructured":"Palumbo A, Triolo S, Argentino C et al. Dose-intensive melphalan with stem cell support (MEL 100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248\u20131253.","journal-title":"Blood"},{"key":"BF1703818_CR13","first-page":"7","volume":"95","author":"S Lenhoff","year":"2000","unstructured":"Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7\u201311.","journal-title":"Blood"},{"key":"BF1703818_CR14","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1182\/blood.V85.11.3077.bloodjournal85113077","volume":"85","author":"JL Harousseau","year":"1995","unstructured":"Harousseau JL, Attal M, Divine M et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood 1995; 85: 3077\u20133085.","journal-title":"Blood"},{"key":"BF1703818_CR15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V93.1.51","volume":"93","author":"DS Siegel","year":"1999","unstructured":"Siegel DS, Desikan KR, Mehta J et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51\u201354.","journal-title":"Blood"},{"key":"BF1703818_CR16","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.02976.x","volume":"114","author":"A Badros","year":"2001","unstructured":"Badros A, Barlogie B, Siegel E et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600\u2013607.","journal-title":"Br J Haematol"},{"key":"BF1703818_CR17","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1182\/blood.V85.2.588.588","volume":"85","author":"G Tricot","year":"1995","unstructured":"Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cells transplants for multiple myeloma: identification of favourable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588\u2013596.","journal-title":"Blood"},{"key":"BF1703818_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1046\/j.1365-2141.1999.01133.x","volume":"104","author":"D Gupta","year":"1999","unstructured":"Gupta D, Bybee A, Cooke F et al. CD34+-selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcome. Br J Haematol 1999; 104: 166\u2013177.","journal-title":"Br J Haematol"},{"key":"BF1703818_CR19","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. Br J Haematol 1998; 102: 1115\u20131123.","journal-title":"Br J Haematol"},{"key":"BF1703818_CR20","first-page":"52","volume":"85","author":"M Tribalto","year":"2000","unstructured":"Tribalto M, Amadori S, Cudillo L et al. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. Haematologica 2000; 85: 52\u201358.","journal-title":"Haematologica"},{"key":"BF1703818_CR21","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1365-2141.1994.tb06731.x","volume":"87","author":"MA Dimopoulos","year":"1994","unstructured":"Dimopoulos MA, Hester J, Huh Y et al. Intensive chemo-therapy with blood progenitor transplantation for primary resistant multiple myeloma. Br J Haematol 1994; 87: 730\u2013734.","journal-title":"Br J Haematol"},{"key":"BF1703818_CR22","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1200\/JCO.1996.14.5.1447","volume":"14","author":"WI Bensinger","year":"1996","unstructured":"Bensinger WI, Rowley SD, Demirer T et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 1996; 14: 1447\u20131456.","journal-title":"J Clin Oncol"},{"key":"BF1703818_CR23","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","volume":"88","author":"BB Bjorkstrand","year":"1996","unstructured":"Bjorkstrand BB, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711\u20134718.","journal-title":"Blood"},{"key":"BF1703818_CR24","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Attal M et al. Comparison of 200\u2009mg\/m2 melphalan and 8\u2009Gy total body irradiation plus 140\u2009mg\/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intregroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731\u2013735.","journal-title":"Blood"},{"key":"BF1703818_CR25","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/sj.bmt.1701182","volume":"21","author":"B Barlogie","year":"1998","unstructured":"Barlogie B, Jagannath S, Naucke S et al. Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 1998; 21: 1101\u20131107.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703818_CR26","first-page":"844","volume":"84","author":"I Majolino","year":"1999","unstructured":"Majolino I, Vignetti M, Meloni G et al. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Haematologica 1999; 84: 844\u2013852.","journal-title":"Haematologica"},{"key":"BF1703818_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0037-1963(01)90013-7","volume":"38","author":"B Bjorkstrand","year":"2001","unstructured":"Bjorkstrand B . European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma. Semin Hematol 2001; 38: 219\u2013225.","journal-title":"Semin Hematol"},{"issue":"Suppl. 1","key":"BF1703818_CR28","first-page":"S206","volume":"21","author":"M Attal","year":"1998","unstructured":"Attal M, Payen C, Facom T et al. Single versus double transplant in myeloma: a randomised trial of the \u2018Intergroupe Francais du Myelome\u2019. Bone Marrow Transplant 1998; 21 (Suppl. 1): S206 (abstract).","journal-title":"Bone Marrow Transplant"},{"key":"BF1703818_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/sj.bmt.1701062","volume":"21","author":"A Alegre","year":"1998","unstructured":"Alegre A, Diaz-Mediavilla J, San-Miguel J et al. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM and PETHEMA. Bone Marrow Transplant 1998; 21: 133\u2013140.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703818_CR30","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/blood.V84.12.4278.bloodjournal84124278","volume":"84","author":"R Alexanian","year":"1994","unstructured":"Alexanian R, Dimopoulos MA, Hester J et al. Early myeloablative therapy for multiple myeloma. Blood 1994; 84: 4278\u20134282.","journal-title":"Blood"},{"key":"BF1703818_CR31","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3109\/07357909609012166","volume":"14","author":"DH Vesole","year":"1996","unstructured":"Vesole DH, Jagannath S, Tricot G et al. Autologous bone marrow and peripheral blood stem cell transplantation in multiple myeloma. Cancer Invest 1996; 14: 378\u2013391.","journal-title":"Cancer Invest"},{"key":"BF1703818_CR32","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1200\/JCO.1999.17.7.2173","volume":"17","author":"DH Vesole","year":"1999","unstructured":"Vesole DH, Crowley JJ, Catchatourian R et al. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol 1999; 17: 2173\u20132179.","journal-title":"J Clin Oncol"},{"key":"BF1703818_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1046\/j.1365-2141.2002.03231.x","volume":"116","author":"G Tricot","year":"2002","unstructured":"Tricot G, Spencer T, Sawyer J et al. Predicting long-term (> or =5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002; 116: 211\u2013217.","journal-title":"Br J Haematol"},{"key":"BF1703818_CR34","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/sj.bmt.1702640","volume":"26","author":"SV Rajkumar","year":"2000","unstructured":"Rajkumar SV, Fonseca R, Dispenzieri A et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000; 26: 979\u2013983.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703818_CR35","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1182\/blood.V85.11.3077.bloodjournal85113077","volume":"85","author":"JL Harousseau","year":"1995","unstructured":"Harousseau JL, Attal M, Divine M et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood 1995; 85: 3077\u20133085.","journal-title":"Blood"},{"key":"BF1703818_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/sj.bmt.1702188","volume":"25","author":"B Sirohi","year":"2000","unstructured":"Sirohi B, Powles R, Treleaven J et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000; 25: 533\u2013539.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703818_CR37","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1046\/j.1365-2141.2000.01979.x","volume":"109","author":"JJ Lahuerta","year":"2000","unstructured":"Lahuerta JJ, Martinez-Lopez J, Grande C et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish registry for transplantation in multiple myeloma. Br J Haematol 2000; 109: 138\u2013147.","journal-title":"Br J Haematol"},{"key":"BF1703818_CR38","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/sj.bmt.1702167","volume":"25","author":"KR Desikan","year":"2000","unstructured":"Desikan KR, Tricot D, Dhodapkar M et al. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant 2000; 25: 483\u2013487.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703818_CR39","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0889-8588(05)70125-8","volume":"13","author":"J Blade","year":"1999","unstructured":"Blade J, Kyle RA . Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukaemia. Hematol Oncol Clin North Am 1999; 13: 1259\u20131272.","journal-title":"Hematol Oncol Clin North Am"},{"key":"BF1703818_CR40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/hon.2900040407","volume":"4","author":"DB Smith","year":"1986","unstructured":"Smith DB, Harris M, Gowland et al. Non-secretory multiple myeloma: a report of 13 cases with a review of the literature. Hematol Oncol 1986; 4: 307\u2013313.","journal-title":"Hematol Oncol"},{"key":"BF1703818_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/sj.bmt.1703093","volume":"28","author":"B Sirohi","year":"2001","unstructured":"Sirohi B, Powles R, Kulkarni S et al. Comparison of new patients with Bence\u2013Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant 2001; 28: 29\u201337.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703818_CR42","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","volume":"92","author":"JP Fermand","year":"1998","unstructured":"Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131\u20133136.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1703818","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703818.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703818.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T23:39:00Z","timestamp":1648078740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1703818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,1]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,2,1]]}},"alternative-id":["BF1703818"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1703818","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2,1]]},"assertion":[{"value":"3 May 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2003","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}